Dr Bryan H. Norman

Medicinal and Bioorganic Chemistry Foundation (MBCF)

Bryan H. Norman received his Ph.D. at Emory University and was an NIH Postdoctoral Fellow at Penn State University.  After three years at Monsanto/Searle, Bryan joined Eli Lilly and Company in 1993, where he led multiple cross functional drug discovery efforts, many of which culminated in clinical candidates for oncology, endocrine and pain indications.  In addition to his expertise in medicinal chemistry, Bryan has significant cross functional drug discovery experience and expertise in additional disciplines, such as biomarkers, pharmacokinetic/pharmacodynamic (PK/PD) relationships, mechanisms of drug metabolism and toxicology.  He has specific expertise in the mechanisms and mitigation strategies to avoid drug-induced liver injury (DILI).  The breadth of his background has led to his service on many Due Diligence teams to assess potential in-license opportunities.  Bryan is a Volume Editor and serves on the Editorial Board of Burger’s Medicinal Chemistry, Drug Discovery and Development.  He is currently on the Board of Directors of the Medicinal and Bioorganic Chemistry Foundation and serves on various grant review committees.  He has published over 45 papers in peer-reviewed scientific journals and given many invited lectures at scientific conferences and universities. His most recent research interests have focused on the identification of mechanisms associated with drug-induced liver injury and the discovery of novel analgesic agents for use in chronic pain.